Damoiseaux C, Merveille A-C, Krafft E, Da Costa A M, Gomart S, Jespers P, Michaux C, Clercx C, Verhoeven C, Mc Entee K
Department of Small Animal Clinical Sciences, Faculty of Veterinary Medicine, Université de Liège, Liège, Belgium.
J Vet Intern Med. 2014 Nov-Dec;28(6):1738-45. doi: 10.1111/jvim.12433. Epub 2014 Oct 13.
In humans, a high concentration of adiponectin is associated with a favorable cardiovascular risk profile whereas, in patients with heart failure (HF), a high concentration of adiponectin is associated with a less favorable prognosis.
HYPOTHESIS/OBJECTIVES: To evaluate the physiological determinants of plasma adiponectin concentration in dogs and the influence of heart disease, myxomatous mitral valve disease (MMVD), and dilated cardiomyopathy (DCM).
One hundred and fourteen client-owned dogs and 9 Beagles from the research colony of the Clinical Veterinary Unit of the University of Liège.
We prospectively measured circulating adiponectin concentration in healthy control dogs (n = 77), dogs with MMVD (n = 22) and dogs with DCM (n = 15) of various degrees of severity. Diagnosis was confirmed by Doppler echocardiography. Plasma adiponectin concentration was measured by a canine-specific sandwich ELISA kit.
An analysis of covariance showed an association between adiponectin concentration and age, neuter status, and heart disease. No association between adiponectin concentration and class of HF, sex, body condition score, body weight, circadian rhythm, or feeding was found. Plasma adiponectin concentration was negatively correlated with age (P = .001). Adiponectin was lower in neutered (P = .008) compared to intact dogs. Circulating adiponectin concentration was increased in dogs with DCM compared to healthy dogs (P = .018) and to dogs with MMVD (P = .014).
Age and neutering negatively influence circulating adiponectin concentration. Plasma adiponectin concentration increased in dogs with DCM. Additional research is required to investigate if this hormone is implicated in the pathophysiology of DCM and associated with clinical outcome.
在人类中,高浓度脂联素与良好的心血管风险状况相关,而在心力衰竭(HF)患者中,高浓度脂联素与较差的预后相关。
假设/目的:评估犬血浆脂联素浓度的生理决定因素以及心脏病、黏液瘤性二尖瓣疾病(MMVD)和扩张型心肌病(DCM)的影响。
114只客户拥有的犬以及来自列日大学临床兽医学部研究群体的9只比格犬。
我们前瞻性地测量了健康对照犬(n = 77)、不同严重程度的MMVD犬(n = 22)和DCM犬(n = 15)的循环脂联素浓度。诊断通过多普勒超声心动图确认。血浆脂联素浓度通过犬特异性夹心ELISA试剂盒测量。
协方差分析显示脂联素浓度与年龄、去势状态和心脏病之间存在关联。未发现脂联素浓度与HF分级、性别、身体状况评分、体重、昼夜节律或喂养之间存在关联。血浆脂联素浓度与年龄呈负相关(P = .001)。与未去势犬相比,去势犬的脂联素水平较低(P = .008)。与健康犬(P = .018)和MMVD犬(P = .014)相比,DCM犬的循环脂联素浓度升高。
年龄和去势对循环脂联素浓度有负面影响。DCM犬的血浆脂联素浓度升高。需要进一步研究来调查这种激素是否参与DCM的病理生理学过程并与临床结果相关。